Sign in
Active, not recruitingNo phase

Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation

Key facts

Who runs it
Region Skane
Where
Australia, Belgium, Estonia, Finland, Germany, Ireland, Italy, Luxembourg, New Zealand, Norway, Saudi Arabia, Singapore, Sweden, Switzerland, and United Kingdom56 sites in 15 countriesChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
3,500 people, planned
Started
17 Aug 2023
Expected to end
Mar 2027
Type of study
Interventional, 8 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Feedback-controlled temperature device
  • High MAP
  • Deep sedation
  • Fever control without a device
  • Low MAP
  • Minimal sedation
Record updated
2 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Out-of-hospital cardiac arrest
  • Sustained ROSC - defined as 20 minutes with signs of circulation without the need for chest compressions
  • Unconsciousness defined as not being able to obey verbal commands (FOUR-score motor response of <4) or being intubated and sedated because of agitation after sustained ROSC
  • Eligible for intensive care without restrictions or limitations
  • Inclusion within 4 hours of ROSC

Who cannot take part

  • On ECMO prior to randomization
  • Previously randomized in the STEPCARE trial
  • Suspected or confirmed intracranial hemorrhage
  • Trauma or hemorrhage being the presumed cause of arrest
  • Pregnancy

This trial has no sites in United States.

It has sites in 15 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The STEPCARE-trial is a 2x2x2 randomised trial studying patients who have been resuscitated from cardiac arrest and who are comatose. It will include three different interventions focusing on sedation targets, temperature targets and mean arterial pressure targets.

The 8 groups in the trial

  • Sedation, temperature device and high MAPExisting treatment, for comparison

    Continuous deep sedation for 36 hours Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of \>85mmHg.

    Treatment: Feedback-controlled temperature device, High MAP, and Deep sedation

  • Sedation, no temperature device and high MAPExisting treatment, for comparison

    Continuous deep sedation for 36 hours. Fever management without a feedback-controlled device. A mean arterial pressure target of \>85mmHg.

    Treatment: High MAP, Deep sedation, and Fever control without a device

  • Sedation, temperature device and low MAPExisting treatment, for comparison

    Continuous deep sedation for 36 hours. Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of \>65mmHg.

    Treatment: Feedback-controlled temperature device, Deep sedation, and Low MAP

  • Sedation, no temperature device and low MAPExisting treatment, for comparison

    Continuous deep sedation for 36 hours. Fever management without a feedback-controlled device. A mean arterial pressure target of \>65mmHg.

    Treatment: Deep sedation, Fever control without a device, and Low MAP

  • Minimal sedation, temperature device and high MAPExisting treatment, for comparison

    Minimal sedation (and early extubation if possible). Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of \>85mmHg.

    Treatment: Feedback-controlled temperature device, High MAP, and Minimal sedation

  • Minimal sedation, no temperature device and high MAPExisting treatment, for comparison

    Minimal sedation (and early extubation if possible). Fever management without a feedback-controlled device. A mean arterial pressure target of \>65mmHg.

    Treatment: High MAP, Fever control without a device, and Minimal sedation

  • Minimal sedation, temperature device and low MAPExisting treatment, for comparison

    Minimal sedation (and early extubation if possible). Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of \>65mmHg.

    Treatment: Feedback-controlled temperature device, Low MAP, and Minimal sedation

  • Minimal sedation, no temperature device and low MAPExisting treatment, for comparison

    Minimal sedation (and early extubation if possible). Fever management without a feedback-controlled device. A mean arterial pressure target of \>65mmHg.

    Treatment: Fever control without a device, Low MAP, and Minimal sedation

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
2 June 2026